Adults 13 to 18, male only, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Condomless Anal Sex ActsPrimary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
The number of condomless anal sex acts (CASA) will be evaluated at all time points using the AIDS-Risk Behavior Assessment (ARBA) adapted for YMSM. At each timepoint, participants were asked to report the past 3 month number of insertive and receptive anal sex acts during which condoms were not used.
Baseline
Group
Value
95% CI
Immediate Intervention
1.53
± 0.29
Delayed Intervention
1.45
± 0.27
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
1.04
± 0.26
Delayed Intervention
1.63
± 0.38
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
1.68
± 0.47
Delayed Intervention
1.21
± 0.25
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
1.70
± 0.36
Delayed Intervention
1.65
± 0.33
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
1.47
± 0.36
Number of Anal Sex PartnersPrimary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
The number of anal sex partners will be evaluated at all time points using the AIDS-Risk Behavior Assessment (ARBA) adapted for YMSM. Participants are asked to report the number of insertive and receptive anal sex partners in their lifetime at the baseline timepoint and then asked to report the number of insertive and receptive anal sex partners in the past 3 months at each of the follow-up timepoints.
Baseline
Group
Value
95% CI
Immediate Intervention
0.95
± 0.11
Delayed Intervention
0.87
± 0.09
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
0.86
± 0.13
Delayed Intervention
0.71
± 0.09
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
0.90
± 0.11
Delayed Intervention
0.84
± 0.10
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
1.00
± 0.13
Delayed Intervention
0.77
± 0.08
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
1.27
± 0.21
Number of Condomless Anal Sex PartnersPrimary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
The number of condomless anal sex (CAS) partners will be evaluated at all time points using the AIDS-Risk Behavior Assessment (ARBA) adapted for YMSM. Participants are asked to report the number of insertive and receptive anal sex partners with whom condoms were not used in their lifetime at the baseline timepoint and then asked to report the number of insertive and receptive anal sex partners with whom condoms were not used in the past 3 months at each of the follow-up timepoints.
Baseline
Group
Value
95% CI
Immediate Intervention
0.53
± 0.08
Delayed Intervention
0.42
± 0.05
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
0.50
± 0.08
Delayed Intervention
0.38
± 0.06
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
0.43
± 0.06
Delayed Intervention
0.47
± 0.06
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
0.63
± 0.11
Delayed Intervention
0.40
± 0.05
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
0.72
± 0.17
Number of Anal Sex Acts Under the Influence of Drugs/AlcoholPrimary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
The number of anal sex acts under the influence of drugs/alcohol will be evaluated at all time points using the AIDS-Risk Behavior Assessment (ARBA) adapted for YMSM. At each timepoint, participants were asked to report the past 3 month number of insertive and receptive anal sex acts during which they had been drinking alcohol or using drugs.
Baseline
Group
Value
95% CI
Immediate Intervention
0.33
± 0.09
Delayed Intervention
0.45
± 0.11
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
0.35
± 0.16
Delayed Intervention
0.42
± 0.14
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
0.35
± 0.18
Delayed Intervention
0.43
± 0.09
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
0.41
± 0.11
Delayed Intervention
0.54
± 0.12
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
0.53
± 0.16
Number of Participants With Self-reported Pre-exposure Prophylaxis (PrEP) UsePrimary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
Participants were asked if they have ever used Pre-exposure Prophylaxis (PrEP) at baseline, if they have used PrEP in the prior 3 months at all timepoints, and if they are currently using PrEP at the time of study visit at all timepoints.
Baseline
Group
Value
95% CI
Immediate Intervention
10
Delayed Intervention
10
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
14
Delayed Intervention
14
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
20
Delayed Intervention
16
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
13
Delayed Intervention
14
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
25
Number of Participants With Self-reported Non-occupational Post-Exposure Prophylaxis (nPEP) UsePrimary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
Participants were asked if they've ever used Non-occupational Post-Exposure Prophylaxis (nPEP) at baseline and if they've used nPEP in the 3 months prior to each study visit timepoint.
Baseline
Group
Value
95% CI
Immediate Intervention
4
Delayed Intervention
6
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
3
Delayed Intervention
4
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
5
Delayed Intervention
8
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
1
Delayed Intervention
3
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
3
Number of Participants With Self-Reported HIV TestingPrimary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
Participants were asked to report how many times they've ever been tested for HIV at baseline and at each follow-up timepoint they were asked how many times they've tested for HIV in the prior 3 months.
Baseline
Group
Value
95% CI
Immediate Intervention
63
Delayed Intervention
55
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
90
Delayed Intervention
79
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
84
Delayed Intervention
69
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
93
Delayed Intervention
69
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
71
Number of Participants With Self-Reported Sexually Transmitted Infection (STI) TestingPrimary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
Participants were asked to report past 3-month testing for sexually transmitted infections (STIs) at each timepoint.
Baseline
Group
Value
95% CI
Immediate Intervention
73
Delayed Intervention
65
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
63
Delayed Intervention
49
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
56
Delayed Intervention
44
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
59
Delayed Intervention
44
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
53
Intent to Have Anal SexSecondary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
Participants were presented with the statement "During the next 3 months, I am not planning to have anal sex" with response options ranging from 1=Very true to 4=Very untrue. The mean value was calculated per group and per timepoint.
Baseline
Group
Value
95% CI
Immediate Intervention
2.35
± 0.06
Delayed Intervention
2.40
± 0.05
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
2.30
± 0.06
Delayed Intervention
2.36
± 0.06
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
2.33
± 0.06
Delayed Intervention
2.35
± 0.06
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
2.42
± 0.06
Delayed Intervention
2.40
± 0.06
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
2.42
± 0.06
Intent to Always Use Condoms During Anal Sex With All Sex PartnersSecondary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
Participants responded to the statement "During the next 3 months, I plan to always use condoms during anal sex with all of my sex partners" with response options ranging from 1=Very true to 4=Very untrue. Mean values were calculated by group for each timepoint.
Baseline
Group
Value
95% CI
Immediate Intervention
3.38
± 0.04
Delayed Intervention
3.41
± 0.04
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
3.45
± 0.05
Delayed Intervention
3.44
± 0.04
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
3.34
± 0.05
Delayed Intervention
3.37
± 0.05
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
3.42
± 0.05
Delayed Intervention
3.38
± 0.04
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
3.35
± 0.05
Intent to Use PrEP as a Strategy to Reduce HIV Infection RiskSecondary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
Participants responded to the statement "I plan to use PrEP as a strategy to reduce my risk for HIV infection during the next three months" with response values ranging from 1=Very true to 4=Very untrue. Mean values were calculated for each group at each timepoint.
Baseline
Group
Value
95% CI
Immediate Intervention
2.67
± 0.06
Delayed Intervention
2.65
± 0.05
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
2.82
± 0.06
Delayed Intervention
2.66
± 0.06
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
2.79
± 0.06
Delayed Intervention
2.66
± 0.06
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
2.74
± 0.06
Delayed Intervention
2.59
± 0.05
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
2.83
± 0.06
Self-efficacy for Safer Sex and Situational Temptation for Unsafe SexSecondary· Baseline, 3, 6, and 9 months (Intervention group); Baseline, 3, 6, 9, and 12 months (Delayed Intervention group)
Participants were asked to respond to 10 questions assessing self-efficacy in practicing condom use and safer sex communication with a partner. A sample item is "if I didn't want to have sex with my partner, I would be able to say no." Response options ranged from 1=Strongly agree to 4=Strongly disagree. Question scores ranged 1-4, values averaged and total scores ranged from 1 to 4, with lower values indicating higher self-efficacy
Baseline
Group
Value
95% CI
Immediate Intervention
1.51
± 0.02
Delayed Intervention
1.52
± 0.02
3-Month Follow-up
Group
Value
95% CI
Immediate Intervention
1.44
± 0.02
Delayed Intervention
1.54
± 0.02
6-Month Follow-up
Group
Value
95% CI
Immediate Intervention
1.50
± 0.02
Delayed Intervention
1.52
± 0.02
9-Month Follow-up
Group
Value
95% CI
Immediate Intervention
1.47
± 0.02
Delayed Intervention
1.55
± 0.02
12-Month Follow-up
Group
Value
95% CI
Delayed Intervention
1.44
± 0.02
Sponsor's own description
The proposed MyPEEPS Mobile intervention is a novel and evidence-driven intervention using mobile technology to deliver HIV prevention information specifically developed for at-risk young men who have sex with men (YMSM). This will be the one of the first studies to test the efficacy of a scaled-up, mobile version of an existing human immunodeficiency virus (HIV) prevention intervention originally developed for, designed by, and piloted for, a diverse group of YMSM.
MyPEEPS Mobile will be tested in an randomized controlled trial with racially and ethnically diverse HIV-negative or unknown status YMSM aged 13-18 at four geographically diverse sites: Birmingham, Chicago, New York City, and Seattle, allowing for increased generalizability of findings.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
· NA
· recruiting
NCT06741631 — MyPEEPS LITE Trial
· NA
· recruiting
NCT05424718 — MyPEEPS Mobile for Young Transgender Men
· NA
· completed
Other recruiting trials for HIV Infections
Currently open trials in the same condition.
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)
· NA
· recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
· Phase 2
· recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall
· Phase 1
· recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention
· NA
· recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad
· Phase 1
· recruiting
Other Columbia University trials
Trials by the same sponsor.
NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp
· Phase 1
· not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
· NA
· not yet recruiting
NCT05992415 — Know Your Pressures NYC
· NA
· not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children
· not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 23 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03167606.